Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 6/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | GRK2 | P25098 | 1/20 | 0.41 |
| ▸ | GRK1 | Q15835 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049822 | 0.85 | CHRNB2 (0.41) | PRPS1 | |
| SCHEMBL6920793 | 0.85 | ICMT (0.47) | PRPS1GRK2GRK1SLC2A1GRIN2B | |
| SCHEMBL12059116 | 0.80 | ADRA1A (0.49) | SLC2A1 | |
| SCHEMBL6922028 | 0.76 | SLC2A1 (0.52) | GRK2GRK1SLC2A1 | |
| SCHEMBL12059005 | 0.75 | ICMT (0.47) | GRK2GRK1SLC2A1 | |
| SCHEMBL12059745 | 0.75 | ACVR1 (0.50) | SLC2A1 | |
| SCHEMBL6921950 | 0.74 | MAPK14 (0.47) | GRK2GRK1SLC2A1GRIN2B | |
| SCHEMBL6922817 | 0.73 | PRCP (0.42) | SLC2A1USP7P2RX7 | |
| SCHEMBL23407332 | 0.72 | NFE2L2 (0.61) | PRPS1 | |
| SCHEMBL23407326 | 0.72 | PRPS1 (0.51) | PRPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | PRPS1 3144/4885CDK9 2035/4885GRK2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.